RARE DISEASE
Generalized arterial calcification of infancy
Generalized arterial calcification of infancy
Generalized arterial calcification of infancy
Synonyms: Idiopathic infantile arterial calcification, Idiopathic obliterative arteriopathy, Infantile arteriosclerosis, Occlusive infantile arteriopathy
Synonyms: Idiopathic infantile arterial calcification, Idiopathic obliterative arteriopathy, Infantile arteriosclerosis, Occlusive infantile arteriopathy
Synonyms: Idiopathic infantile arterial calcification, Idiopathic obliterative arteriopathy, Infantile arteriosclerosis, Occlusive infantile arteriopathy
Drug discovery
2
drugs
With orphan designations
Overview
Generalized Arterial Calcification of Infancy (GACI) is a rare, autosomal recessive disorder caused by mutations in ENPP1 (75% of cases) or ABCC6 genes, leading to deficient pyrophosphate levels and widespread calcification of large/medium arteries. Presenting prenatally or in infancy with heart failure, hypertension, and respiratory distress, it carries ~50% mortality within the first year. Survivors may develop hypophosphatemic rickets, pseudoxanthoma elasticum-like symptoms, or hearing loss. Current management includes bisphosphonates, antihypertensives, and emerging enzyme replacement therapies [1][6][16].
Burden
Mortality: Up to 55% in infancy, primarily from myocardial infarction or heart failure [6][13].
Morbidity: Chronic hypertension, rickets, hearing loss, and multisystem complications requiring lifelong multidisciplinary care [5][13][16].
Healthcare impact: High costs due to intensive neonatal care, imaging, and specialty management [3][13].
Therapies
Bisphosphonates (e.g., etidronate) to reduce calcification, ideally initiated early [1][7][18].
Sodium thiosulfate (calcium chelation) and antihypertensive therapy [2][14].
Emerging therapies: ENPP1 enzyme replacement, antibody-targeted nanoparticle chelation, and prenatal etidronate trials [3][14][18].
Categories: rare circulatory system diseases, rare genetic diseases
Research Papers
145 drug discovery papers about Generalized arterial calcification of infancy, with 2 first-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:
145 drug discovery papers about Generalized arterial calcification of infancy, with 2 first-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:
2026-08-13 | When Arteries Harden Early: A Case of Generalized Arterial Calcification of Infancy
Generalized arterial calcification of infancy (GACI) is a rare, often fatal, autosomal recessive genetic disorder, primarily caused by mutations in the ENPP1 or ABCC6 genes. While most GACI cases are associated with ENPP1 mutations (GACI type 1), a minority are linked to ABCC6 variants (GACI type 2). We report a 30-month-old female with severe, treatment-resistant hypertension. Ultrasonography and computed tomography angiography revealed calcifications in medium- to large-caliber arteries, raising the suspicion of GACI. Next-generation sequencing identified a heterozygous nonsense mutation in exon 23 of the ABCC6 gene, confirming the diagnosis. The patient was initiated on a combination of antihypertensive medications and was later started on bisphosphonate therapy. At last follow-up, the child was clinically stable. This case highlights the importance of early radiological recognition and genetic testing in GACI.
2026-05-26 | Generalized Arterial Calcification of Infancy (GACI): State of the Art and Clinical Perspectives.
Generalized Arterial Calcification of Infancy (GACI) is a rare autosomal recessive disorder characterized by pathological calcium deposition in large and medium-sized arteries, leading to severe cardiovascular complications such as hypertension, heart failure, and stroke. The mortality rate is approximately 50% within the first six months of life if untreated. The disease is primarily caused by mutations in the ENPP1 or ABCC6 genes, resulting in a deficiency of inorganic pyrophosphate (PPi), a key inhibitor of arterial calcification. This review provides a comprehensive overview of the pathophysiology, genetic basis, and clinical features of GACI. In addition, we summarize current and emerging therapeutic strategies, including enzyme replacement therapy with recombinant ENPP1 (INZ-701), critically discussing available preclinical and early clinical evidence, as well as current limitations.
2026-05-18 | Long-term survival and phenotypic expansion in siblings with generalized arterial calcification of infancy.
Generalized arterial calcification of infancy (GACI) is a rare, autosomal recessive disorder caused by pathogenic variants in ENPP1 or ABCC6. While typically fatal in infancy, survival into childhood is increasingly recognized. We report a family with 3 affected siblings homozygous for an ENPP1 variant (c.1367G > A, p.Arg456Gln). The oldest died in infancy, the surviving 2 received early bisphosphonate therapy. Both survivors demonstrate persistent vascular calcifications, early-onset pseudoxanthoma elasticum (PXE)-like skin lesions, and chronic hypophosphatemia without radiographic rickets. Uniquely, this report contrasts the clinical course of a late preterm sibling against a sibling born extremely premature. Additional findings include auricular cartilage, renal and retinal calcifications, highlighting the systemic nature of ENPP1 deficiency. Our report expands the phenotypic spectrum of ENPP1-related GACI.
2026-03-04 | Diffuse Vascular Calcification Presenting as Refractory Pulmonary Hypertension in a Neonate: A Diagnostic Unravelling
Background: Persistent pulmonary hypertension of the newborn (PPHN) is a recognized cause of neonatal hypoxemic respiratory failure, most commonly associated with parenchymal lung disease or maladaptation of pulmonary circulation. Rarely, severe and refractory pulmonary hypertension may signal an underlying systemic vasculopathy. Generalized arterial calcification of infancy (GACI) is a rare genetic disorder characterized by diffuse arterial wall calcification and intimal proliferation, frequently resulting from ENPP1 mutations. Early manifestations may mimic common neonatal cardiopulmonary conditions, leading to diagnostic delay. Case Presentation: We report a late preterm neonate (34+5 weeks) presenting at birth with severe respiratory failure and persistent hypoxemia requiring mechanical ventilation. Initial evaluation suggested respiratory distress syndrome with severe pulmonary hypertension. Despite optimized ventilatory support, surfactant therapy, pulmonary vasodilators, and inotropic support, pulmonary hypertension remained refractory. The emergence of systemic hypertension, depressed biventricular function, and differential oxygen saturations prompted further evaluation. Serial imaging revealed progressive arterial wall echogenicity on echocardiography and abdominal ultrasonography. Plain chest radiography demonstrated linear, tubular radio-opaque densities tracking along major vascular pathways, mimicking intravascular lines. Contrast-enhanced CT angiography confirmed extensive circumferential calcification involving the thoracic and abdominal aorta, pulmonary arteries, and major systemic branches with preserved luminal patency. Genetic testing identified a pathogenic ENPP1 mutation, establishing the diagnosis of generalized arterial calcification of infancy. The patient was managed with intensive cardiopulmonary support, antihypertensive therapy, and bisphosphonate treatment. Conclusion: This case highlights generalized arterial calcification of infancy as an important differential diagnosis in neonates with refractory pulmonary hypertension, particularly when accompanied by early systemic hypertension and atypical vascular imaging findings. Careful review of plain radiographs and progressive arterial wall echogenicity on ultrasound may provide early diagnostic clues. Prompt recognition and genetic confirmation are essential for targeted management, prognostication, and family counseling in this rare but potentially fatal neonatal vasculopathy.
2026-03-02 | Optimizing diagnosis and management of patients with ENPP1 deficiency: an expert opinion.
PURPOSE: Ectonucleotide pyrophosphate/phosphodiesterase family member 1 (ENPP1) deficiency is a rare genetic disorder caused by loss-of-function ENPP1 gene mutations. Characterized by abnormally low circulating inorganic pyrophosphate concentrations, bone hypomineralization, soft tissue calcification, and arterial stenosis, ENPP1 deficiency is associated with a phenotypic spectrum that includes generalized arterial calcification of infancy type 1 (GACI1) and autosomal recessive hypophosphatemic rickets type 2 (ARHR2). Despite phenotypic differences, patients with GACI1 and ARHR2 have a marked, lifelong physical and emotional burden, with a negative impact on quality of life. METHODS: A scientific board, comprising seven specialist physicians (endocrinologists, nephrologists, and pediatricians) practicing in Italy, held two virtual meetings to exchange knowledge regarding real-world clinical experience of GACI1 and ARHR2 using case examples, and to discuss strategies on how to increase disease awareness and optimize the diagnosis and management of these patients. RESULTS: Five real-world clinical cases are described. The specialist physicians also provide guidance for optimizing the management pathway for patients with ENPP1 deficiency. Early identification of the clinical signs of disease, in combination with comprehensive diagnostic and follow-up testing, is essential for effective patient management. CONCLUSION: Early and accurate identification of ENPP1 deficiency by healthcare providers and comprehensive diagnostic testing is essential for the effective management of patients with GACI1 and ARHR2. Consistent follow-up is key to preventing complications and adverse outcomes. Although treatment options are limited, novel therapies are currently under clinical development.
2026-08-13 | When Arteries Harden Early: A Case of Generalized Arterial Calcification of Infancy
Generalized arterial calcification of infancy (GACI) is a rare, often fatal, autosomal recessive genetic disorder, primarily caused by mutations in the ENPP1 or ABCC6 genes. While most GACI cases are associated with ENPP1 mutations (GACI type 1), a minority are linked to ABCC6 variants (GACI type 2). We report a 30-month-old female with severe, treatment-resistant hypertension. Ultrasonography and computed tomography angiography revealed calcifications in medium- to large-caliber arteries, raising the suspicion of GACI. Next-generation sequencing identified a heterozygous nonsense mutation in exon 23 of the ABCC6 gene, confirming the diagnosis. The patient was initiated on a combination of antihypertensive medications and was later started on bisphosphonate therapy. At last follow-up, the child was clinically stable. This case highlights the importance of early radiological recognition and genetic testing in GACI.
2026-05-26 | Generalized Arterial Calcification of Infancy (GACI): State of the Art and Clinical Perspectives.
Generalized Arterial Calcification of Infancy (GACI) is a rare autosomal recessive disorder characterized by pathological calcium deposition in large and medium-sized arteries, leading to severe cardiovascular complications such as hypertension, heart failure, and stroke. The mortality rate is approximately 50% within the first six months of life if untreated. The disease is primarily caused by mutations in the ENPP1 or ABCC6 genes, resulting in a deficiency of inorganic pyrophosphate (PPi), a key inhibitor of arterial calcification. This review provides a comprehensive overview of the pathophysiology, genetic basis, and clinical features of GACI. In addition, we summarize current and emerging therapeutic strategies, including enzyme replacement therapy with recombinant ENPP1 (INZ-701), critically discussing available preclinical and early clinical evidence, as well as current limitations.
2026-05-18 | Long-term survival and phenotypic expansion in siblings with generalized arterial calcification of infancy.
Generalized arterial calcification of infancy (GACI) is a rare, autosomal recessive disorder caused by pathogenic variants in ENPP1 or ABCC6. While typically fatal in infancy, survival into childhood is increasingly recognized. We report a family with 3 affected siblings homozygous for an ENPP1 variant (c.1367G > A, p.Arg456Gln). The oldest died in infancy, the surviving 2 received early bisphosphonate therapy. Both survivors demonstrate persistent vascular calcifications, early-onset pseudoxanthoma elasticum (PXE)-like skin lesions, and chronic hypophosphatemia without radiographic rickets. Uniquely, this report contrasts the clinical course of a late preterm sibling against a sibling born extremely premature. Additional findings include auricular cartilage, renal and retinal calcifications, highlighting the systemic nature of ENPP1 deficiency. Our report expands the phenotypic spectrum of ENPP1-related GACI.
2026-03-04 | Diffuse Vascular Calcification Presenting as Refractory Pulmonary Hypertension in a Neonate: A Diagnostic Unravelling
Background: Persistent pulmonary hypertension of the newborn (PPHN) is a recognized cause of neonatal hypoxemic respiratory failure, most commonly associated with parenchymal lung disease or maladaptation of pulmonary circulation. Rarely, severe and refractory pulmonary hypertension may signal an underlying systemic vasculopathy. Generalized arterial calcification of infancy (GACI) is a rare genetic disorder characterized by diffuse arterial wall calcification and intimal proliferation, frequently resulting from ENPP1 mutations. Early manifestations may mimic common neonatal cardiopulmonary conditions, leading to diagnostic delay. Case Presentation: We report a late preterm neonate (34+5 weeks) presenting at birth with severe respiratory failure and persistent hypoxemia requiring mechanical ventilation. Initial evaluation suggested respiratory distress syndrome with severe pulmonary hypertension. Despite optimized ventilatory support, surfactant therapy, pulmonary vasodilators, and inotropic support, pulmonary hypertension remained refractory. The emergence of systemic hypertension, depressed biventricular function, and differential oxygen saturations prompted further evaluation. Serial imaging revealed progressive arterial wall echogenicity on echocardiography and abdominal ultrasonography. Plain chest radiography demonstrated linear, tubular radio-opaque densities tracking along major vascular pathways, mimicking intravascular lines. Contrast-enhanced CT angiography confirmed extensive circumferential calcification involving the thoracic and abdominal aorta, pulmonary arteries, and major systemic branches with preserved luminal patency. Genetic testing identified a pathogenic ENPP1 mutation, establishing the diagnosis of generalized arterial calcification of infancy. The patient was managed with intensive cardiopulmonary support, antihypertensive therapy, and bisphosphonate treatment. Conclusion: This case highlights generalized arterial calcification of infancy as an important differential diagnosis in neonates with refractory pulmonary hypertension, particularly when accompanied by early systemic hypertension and atypical vascular imaging findings. Careful review of plain radiographs and progressive arterial wall echogenicity on ultrasound may provide early diagnostic clues. Prompt recognition and genetic confirmation are essential for targeted management, prognostication, and family counseling in this rare but potentially fatal neonatal vasculopathy.
2026-03-02 | Optimizing diagnosis and management of patients with ENPP1 deficiency: an expert opinion.
PURPOSE: Ectonucleotide pyrophosphate/phosphodiesterase family member 1 (ENPP1) deficiency is a rare genetic disorder caused by loss-of-function ENPP1 gene mutations. Characterized by abnormally low circulating inorganic pyrophosphate concentrations, bone hypomineralization, soft tissue calcification, and arterial stenosis, ENPP1 deficiency is associated with a phenotypic spectrum that includes generalized arterial calcification of infancy type 1 (GACI1) and autosomal recessive hypophosphatemic rickets type 2 (ARHR2). Despite phenotypic differences, patients with GACI1 and ARHR2 have a marked, lifelong physical and emotional burden, with a negative impact on quality of life. METHODS: A scientific board, comprising seven specialist physicians (endocrinologists, nephrologists, and pediatricians) practicing in Italy, held two virtual meetings to exchange knowledge regarding real-world clinical experience of GACI1 and ARHR2 using case examples, and to discuss strategies on how to increase disease awareness and optimize the diagnosis and management of these patients. RESULTS: Five real-world clinical cases are described. The specialist physicians also provide guidance for optimizing the management pathway for patients with ENPP1 deficiency. Early identification of the clinical signs of disease, in combination with comprehensive diagnostic and follow-up testing, is essential for effective patient management. CONCLUSION: Early and accurate identification of ENPP1 deficiency by healthcare providers and comprehensive diagnostic testing is essential for the effective management of patients with GACI1 and ARHR2. Consistent follow-up is key to preventing complications and adverse outcomes. Although treatment options are limited, novel therapies are currently under clinical development.
Access all drug discovery papers and probability of success in trials forecasts:
Access all drug discovery papers and probability of success in trials forecasts:
Drug Discovery Landscape
2 orphan drug designations for Generalized arterial calcification of infancy.
2 orphan drug designations for Generalized arterial calcification of infancy.
Drug | Therapy type | Regulator | Orphan designation | Approval | Sponsor |
|---|---|---|---|---|---|
Recombinant human ectonucleotide pyrophosphatase/phosphodiesterase 1 fused to the Fc fragment of IgG1 | proteins | EMA | 2018-07-31 | — | Inozyme Pharma Ireland Ltd |
extracellular domain of Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 fused to the Fc region of human IgG1 | proteins | FDA | 2018-06-11 | — | Inozyme Pharma Inc. |
Let's accelerate rare disease drug discovery
Let's accelerate drug discovery
Get access to Explority AI's forecasts to outperform average preclinical success rates. Whether you're expanding your R&D pipeline, evaluating a partnership, or simply have a question — we'd love to hear from you.